Pneumococcal Polyvalent Vaccine
Adult Diffuse Mixed Cell Lymphoma
Mayo ClinicvaccineEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Adult Diffuse Mixed Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cefepime Wake Forest University Health Sciences | Phase 1 | CC |
Same molecule, other indications
Pneumococcal Polyvalent Vaccine is also rated in:
pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →